Implications of different CA 15-3 levels according to breast cancer subtype at initial diagnosis of recurrent or metastatic breast cancer

Oncology

Volumn 82, Issue 3, 2012, Pages 180-187

  Park, Silvia ^a   Ahn, Hee Kyung ^a   Park, Lee Chun ^a   Hwang, Deok Won ^a   Ji, Jun Ho ^a   Maeng, Chi Hoon ^a   Cho, Su Hee ^a   Lee, Ji Yean ^a   Park, Kyung Tae ^b   Ahn, Jin Seok ^a   Park, Yeon Hee ^a   Im, Young Hyuck ^a  

^a Samsung Medical Center   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Breast cancer; Hormone receptors; Mucin 1 expression

Indexed keywords

CA 15-3 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; MUCIN 1; PROGESTERONE RECEPTOR;

ADOLESCENT; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; HUMANS; MIDDLE AGED; MUCIN-1; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84862822752     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000336081     Document Type: Article

References (38)

1. Sorlie T, Wang Y, Xiao C, Johnsen H, Naume B, Samaha RR, Borresen-Dale AL: Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: Gene expression analyses across three different platforms. BMC Genomics 2006; 7: 127.
2. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, Demeter J, Perou CM, Lonning PE, Brown PO, Borresen-Dale AL, Botstein D: Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003; 100: 8418-8423. (Pubitemid 36842560)
3. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lonning P, Borresen-Dale AL: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98: 10869-10874. (Pubitemid 32878711)
4. Polyak K: Breast cancer: origins and evolution. J Clin Invest 2007; 117: 3155-3163. (Pubitemid 350096968)
5. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D: Molecular portraits of human breast tumours. Nature 2000; 406: 747-752.
6. Park SY, Lee HE, Li H, Shipitsin M, Gelman R, Polyak K: Heterogeneity for stem cell-related markers according to tumor subtype and histologic stage in breast cancer. Clin Cancer Res 2010; 16: 876-887.
7. Smid M, Wang Y, Zhang Y, Sieuwerts AM, Yu J, Klijn JG, Foekens JA, Martens JW: Subtypes of breast cancer show preferential site of relapse. Cancer Res 2008; 68: 3108-3114.
8. Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, Hess KR, Stec J, Ayers M, Wagner P, Morandi P, Fan C, Rabiul I, Ross JS, Hortobagyi GN, Pusztai L: Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005; 11: 5678-5685. (Pubitemid 41170290)
9. Lim E, Vaillant F, Wu D, Forrest NC, Pal B, Hart AH, Asselin-Labat ML, Gyorki DE, Ward T, Partanen A, Feleppa F, Huschtscha LI, Thorne HJ, Fox SB, Yan M, French JD, Brown MA, Smyth GK, Visvader JE, Lindeman GJ: Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med 2009; 15: 907-913.
10. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC: Race, breast cancer subtypes, and survival in the Carolina breast cancer study. JAMA 2006; 295: 2492-2502. (Pubitemid 43854964)
11. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, Akslen LA, Ragaz J, Gown AM, Gilks CB, van de Rijn M, Perou CM: Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004; 10: 5367-5374. (Pubitemid 39100473)
12. Chakraborty S, Bonthu N, Swanson BJ, Batra SK: Role of mucins in the skin during benign and malignant conditions. Cancer Lett 2011; 301: 127-141.
13. Rachagani S, Torres MP, Moniaux N, Batra SK: Current status of mucins in the diagnosis and therapy of cancer. Biofactors 2009; 35: 509-527.
14. Singh AP, Senapati S, Ponnusamy MP, Jain M, Lele SM, Davis JS, Remmenga S, Batra SK: Clinical potential of mucins in diagnosis, prognosis, and therapy of ovarian cancer. Lancet Oncol 2008; 9: 1076-1085.
15. Wittel UA, Goel A, Varshney GC, Batra SK: Mucin antibodies-new tools in diagnosis and therapy of cancer. Front Biosci 2001; 6:D1296-D1310.
16. Rakha EA, Boyce RW, Abd El-Rehim D, Kurien T, Green AR, Paish EC, Robertson JF, Ellis IO: expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5ac and MUC6) and their prognostic significance in human breast cancer. Mod Pathol 2005; 18: 1295-1304. (Pubitemid 41348648)
17. Sonora C, Mazal D, Berois N, Buisine MP, Ubillos L, Varangot M, Barrios E, Carzoglio J, Aubert JP, Osinaga E: immunohistochemical analysis of MUC5b apomucin expression in breast cancer and non-malignant breast tissues. J Histochem Cytochem 2006; 54: 289-299. (Pubitemid 43291273)
18. Blair SL, Wang-Rodriguez J, Cortes-Mateos MJ, Messmer D, Sandoval S, Messmer B, Trogler W, Kummel A: enhanced touch preps improve the ease of interpretation of intraoperative breast cancer margins. Am Surg 2007; 73: 973-976. (Pubitemid 351396546)
19. Workman HC, Miller JK, Ingalla EQ, Kaur RP, Yamamoto DI, Beckett LA, Young LJ, Cardiff RD, Borowsky AD, Carraway KL, Sweeney C, Carraway KL 3rd: the membrane mucin MUC4 is elevated in breast tumor lymph node metastases relative to matched primary tumors and confers aggressive properties to breast cancer cells. Breast Cancer Res 2009; 11:R70.
20. Yuan S, Shi C, Liu L, Han W: MUC1-based recombinant Bacillus Calmette-Guerin vaccines as candidates for breast cancer immunotherapy. Expert Opin Biol Ther 2010; 10: 1037-1048.
21. Singh R, Bandyopadhyay D: MUC1: a target molecule for cancer therapy. Cancer Biol Ther 2007; 6: 481-486. (Pubitemid 47328319)
22. Mukhopadhyay P, Chakraborty S, Ponnusamy MP, Lakshmanan I, Jain M, Batra SK: Mucins in the pathogenesis of breast cancer: implications in diagnosis, prognosis and therapy. Biochim Biophys Acta 2011; 1815: 224-240.
23. O'Brien CS, Farnie G, Howell SJ, Clarke RB: Breast cancer stem cells and their role in resistance to endocrine therapy. Horm Cancer 2011; 2: 91-103.
24. Molyneux G, Regan J, Smalley MJ: Mammary stem cells and breast cancer. Cell Mol Life Sci 2007; 64: 3248-3260.
25. Duffy MJ: Biochemical markers in breast cancer: which ones are clinically useful? Clin Biochem 2001; 34: 347-352. (Pubitemid 32777841)
26. Rasmussen BB, Hilgers J, Hilkens J: The influence of formalin and paraffin embedding on the immunohistochemical reaction of monoclonal antibodies applied to female breast tissue. Acta Pathol Microbiol Immunol Scand A 1984; 92: 167-175. (Pubitemid 14090531)
27. Duffy MJ: CA 15-3 and related mucins as circulating markers in breast cancer. Ann Clin Biochem 1999; 36: 579-586. (Pubitemid 29410709)
28. Klee GG, Schreiber WE: MUC1 gene-derived glycoprotein assays for monitoring breast cancer (CA 15-3, CA 27.29, BR): are they measuring the same antigen? Arch Pathol Lab Med 2004; 128: 1131-1135. (Pubitemid 39313366)
29. Duffy MJ, Evoy D, McDermott EW: CA 15-3: uses and limitation as a biomarker for breast cancer. Clin Chim Acta 2010; 411: 1869-1874.
30. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF, Bast RC Jr: American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007; 25: 5287-5312. (Pubitemid 350232263)
31. Bensouda Y, Andre F, Boulet T, Al-Ghuzlan A, Conforti R, Troalen F, Bourgier C, Errihani H, Spielmann M, Delaloge S: Prevalence of elevated serum CA 15-3 at time of metastatic relapse of breast cancer and correlation with hormone receptor status (article in French). Bull Cancer 2009; 96: 923-928.
32. Tampellini M, Berruti A, Gerbino A, Buniva T, Torta M, Gorzegno G, Faggiuolo R, Cannone R, Farris A, Destefanis M, Moro G, Deltetto F, Dogliotti L: Relationship between CA 15-3 serum levels and disease extent in predicting overall survival of breast cancer patients with newly diagnosed metastatic disease. Br J Cancer 1997; 75: 698-702. (Pubitemid 27091084)
33. Mukhopadhyay P, Chakraborty S, Ponnusamy MP, Lakshmanan I, Jain M, Batra SK: Mucins in the pathogenesis of breast cancer: implications in diagnosis, prognosis and therapy. Biochim Biophys Acta 2011; 1815: 224-240.
34. Loo LW, Grove DI, Williams EM, Neal CL, Cousens LA, Schubert EL, Holcomb IN, Massa HF, Glogovac J, Li CI, Malone KE, Daling JR, Delrow JJ, Trask BJ, Hsu L, Porter PL: Array comparative genomic hybridization analysis of genomic alterations in breast cancer subtypes. Cancer Res 2004; 64: 8541-8549. (Pubitemid 39552066)
35. Massarweh S, Osborne CK, Jiang S, Wakeling AE, Rimawi M, Mohsin SK, Hilsenbeck S, Schiff R: Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptorpositive, HER-2/NEU-positive breast cancer. Cancer Res 2006; 66: 8266-8273. (Pubitemid 44299196)
36. Park YH, Lee S, Cho EY, Choi YL, Lee JE, Nam SJ, Yang JH, Ahn JS, Im YH: Patterns of relapse and metastatic spread in HER2-overexpressing breast cancer according to estrogen receptor status. Cancer Chemother Pharmacol 2010; 66: 507-516.
37. Ren J, Agata N, Chen D, Li Y, Yu WH, Huang L, Raina D, Chen W, Kharbanda S, Kufe D: Human MUC1 carcinoma-associated protein confers resistance to genotoxic anticancer agents. Cancer Cell 2004; 5: 163-175. (Pubitemid 38283802)
38. Duffy MJ: Serum tumor markers in breast cancer: are they of clinical value? Clin Chem 2006; 52: 345-351.